Brandon Capital Partners, an Australian life science venture capital firm, expanded its operations into the United States.
The firm opened a Palo Alto office which will be led by Venture Partner J. Leighton Read, MD, an industry veteran and investor.
Led by Managing Director Dr. Chris Nave, Brandon Capital Partners manages the Medical Research Commercialisation Fund (MRCF), a collaboration of more than 50 of Australia’s medical research institutes and hospitals, which has to date funded 24 startups that are developing technologies originating from these institutions.
These include two significant exits:
– Fibrotech Therapeutics, acquired by Shire in 2014, and
– Spinifex Pharmaceuticals, acquired by Novartis in 2015.
In spring of 2015, Brandon Capital Partners announced the closing of the third MRCF fund, an AU$200m fund, which will continue to support and develop startups from the MRCF network.
The firm has Australian offices in Melbourne and Sydney.